Impact of prior smoking exposure and COPD comorbidity on treatment response to monoclonal antibodies in patients with severe asthma

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Morobeid has nothing to disclose.

Conflict of interest: Dr. Pizarro reports personal fees from Astra Zeneca, personal fees from Novartis, during the conduct of the study; personal fees from AstraZeneca, outside the submitted work; .

Conflict of interest: Dr. Biener has nothing to disclose.

Conflict of interest: Dr. Ulrich-Merzenich reports grants from Novartis, during the conduct of the study; grants from Novartis, outside the submitted work.

Conflict of interest: Dr. Kuetting has nothing to disclose.

Conflict of interest: Dr. Nickenig has nothing to disclose.

Conflict of interest: Dr. Skowasch reports personal fees from Astra Zeneca, personal fees from Novartis, personal fees from GSK, during the conduct of the study; personal fees from AstraZeneca, personal fees from Novartis, personal fees from GSK, outside the submitted work; .